Hepatocellular carcinoma: Review of current treatment with a focus on targeted molecular therapies

Therapeutic Advances in Gastroenterology

Volumn 3, Issue 1, 2010, Pages 55-66

  Olsen, Sonja K ^a   Brown, Robert S ^a   Siegel, Abby B ^a  

^a New York Presbyterian Hospital ^*  (United States)

Author keywords

Hepatocellular carcinoma (HCC); Molecular therapies; Novel agents; Treatment

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEMCITABINE; OXALIPLATIN; SORAFENIB; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; FATIGUE; GENE TARGETING; GENETIC ANALYSIS; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MOLECULAR THERAPY; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

EID: 77953370881     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09346669     Document Type: Review

References (82)

1. Abou-Alfa, G.K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A. et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300.
2. Asnacios, A., Fartoux, L., Romano, O., Tesmoingt, C., Louafi, S.S., Mansoubakht, T. et al. (2008) Gemcitabine plus oxaliplatin (Gemox) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 112: 2733-2739.
3. Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G. et al. (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259.
4. Bosch, F.X., Ribes, J., Cleries, R. and Diaz, M. ( 2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, v.
5. Bruix, J., Hessheimer, A.J., Forner, A., Boix, L., Vilana, R. and Llovet, J.M. ( 2006) New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25: 3848-3856.
6. Bruix, J. and Llovet, J.M. ( 2003) HCC surveillance: who is the target population? Hepatology 37: 507-509.
7. Bruix, J., Sala, M. and Llovet, J.M. ( 2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127: S179-S188
8. Bruix, J. and Sherman, M. ( 2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236.
9. Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K. et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430.
10. Burrel, M., Llovet, J.M., Ayuso, C., Iglesias, C., Sala, M., Miquel, R. et al. (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38: 1034-1042.
11. Chapman, W.C., Majella Doyle, M.B., Stuart, J.E., Vachharajani, N., Crippin, J.S., Anderson, C.D. et al. (2008) Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 248: 617-625.
12. Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S. et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
13. Concejero, A., Chen, C.L., Wang, C.C., Wang, S.H., Lin, C.C., Liu, Y.W. et al. (2008) Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation 85: 398-406.
14. de Ledinghen, V., Laharie, D., Lecesne, R., Le Bail, B., Winnock, M., Bernard, P.H. et al. (2002) Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 14: 159-165.
15. Duffy, J.P., Vardanian, A., Benjamin, E., Watson, M., Farmer, D.G., Ghobrial, R.M. et al. (2007) Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246: 502-509, discussion 509-511.
16. El-Serag, H.B., Marrero, J.A., Rudolph, L. and Reddy, K.R. ( 2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763.
17. El-Serag, H.B. and Mason, A.C. ( 1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750.
18. Fisher, R.A., Kulik, L.M., Freise, C.E., Lok, A.S., Shearon, T.H., Brown Jr, R.S. et al. (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7: 1601-1608.
19. Forner, A., Hessheimer, A.J., Isabel Real, M. and Bruix, J. ( 2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60: 89-98.
20. Fouzas, I., Sotiropoulos, G.C., Lang, H., Nadalin, S., Beckebaum, S., Sgourakis, G. et al. (2008) Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria. Transplant Proc 40: 3185-3188.
21. Hanahan, D. and Weinberg, R.A. ( 2000) The hallmarks of cancer. Cell 100: 57-70.
22. Heuer, M., Benko, T., Cicinnati, V.R., Kaiser, G.M., Sotiropoulos, G.C., Baba, H.A. et al. (2009) Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines. Transplant Proc 41: 359-365.
23. Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D.Y., Camargo, A. et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
24. Hoshida, Y., Villanueva, A. and Llovet, J.M. (2009) Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 3: 101-103.
25. Huynh, H., Chow, K.P., Soo, K.C., Toh, H.C., Choo, S.P., Foo, K.F. et al. (2008) Rad001 (Everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 7: 1371-1380.
26. Huynh, H., Ngo, V.C., Koong, H.N., Poon, D., Choo, S.P., Thng, C.H. et al. (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med [In press].
27. Jiang, X.Z., Yan, L.N., Wen, T.F., Li, B., Zeng, Y., Zhao, J.C. et al. (2008) University of California at San Francisco criteria can be applied to living donor liver transplantation for hepatocellular carcinoma: single-center preliminary results in 27 patients. Transplant Proc 40: 1476-1480.
28. Kamada, K., Kitamoto, M., Aikata, H., Kawakami, Y., Kono, H., Imamura, M. et al. (2002) Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 184: 284-290.
29. Koda, M., Murawaki, Y., Mitsuda, A., Oyama, K., Okamoto, K., Idobe, Y. et al. (2001) Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92: 1516-1524.
30. Lee, J.S. and Thorgeirsson, S.S. ( 2004) Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 127: S51-S55
31. Lee, S.G., Hwang, S., Moon, D.B., Ahn, C.S., Kim, K.H., Sung, K.B. et al. (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14: 935-945.
32. Lencioni, R.A., Allgaier, H.P., Cioni, D., Olschewski, M., Deibert, P., Crocetti, L. et al. (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228: 235-240.
33. Libbrecht, L., Bielen, D., Verslype, C., Vanbeckevoort, D., Pirenne, J., Nevens, F. et al. (2002) Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 8: 749-761.
34. Lin, S.M., Lin, C.J., Lin, C.C., Hsu, C.W. and Chen, Y.C. ( 2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 127: 1714-1723.
35. Llovet, J.M., Bru, C. and Bruix, J. ( 1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19: 329-338.
36. Llovet, J.M. and Bruix, J. ( 2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442.
37. Llovet, J.M. ( 2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterology 40: 225-35.
38. Llovet, J.M. and Bruix, J. ( 2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
39. Llovet, J.M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M.I., Schwartz, M. et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131: 1758-1767.
40. Llovet, J.M., Di Bisceglie, A.M., Bruix, J., Kramer, B.S., Lencioni, R., Zhu, A.X. et al. (2008 a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
41. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F. et al. (2008 b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
42. Marrero, J.A., Feng, Z., Wang, Y., Nguyen, M.H., Befeler, A.S., Roberts, L.R. et al. (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110-118.
43. Mazzaferro, V., Llovet, J.M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L. et al. (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10: 35-43.
44. Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F. et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699.
45. Miller, A.A., Murry, D.J., Owzar, K., Hollis, D.R., Kennedy, E.B., Abou-Alfa, G. et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27: 1800-1805.
46. Moon, W.S., Rhyu, K.H., Kang, M.J., Lee, D.G., Yu, H.C., Yeum, J.H. et al. (2003) Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16: 552-557.
47. Nocera, A., Andorno, E., Tagliamacco, A., Morelli, N., Bottino, G., Ravazzoni, F. et al. (2008) Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 40: 1950-1952.
48. Orlando, A., Leandro, G., Olivo, M., Andriulli, A. and Cottone, M. (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104: 514-524.
49. Otto, G., Herber, S., Heise, M., Lohse, A.W., Monch, C., Bittinger, F. et al. (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12: 1260-1267.
50. Ozanne, B.W., Spence, H.J., McGarry, L.C. and Hennigan, R.F. ( 2007) Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1-10.
51. Pandey, D., Wai, C.T., Lee, K.H. and Tan, K.C. ( 2008) Living donor liver transplantation for hepatocellular carcinoma: a single centre experience. Indian J Gastroenterol 27: 148-152.
52. Philip, P.A., Mahoney, M.R., Allmer, C., Thomas, J., Pitot, H.C., Kim, G. et al. (2005) Phase II study of erlotinib (Osi-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663.
53. Pinter, M., Sieghart, W., Graziadei, I., Vogel, W., Maieron, A., Konigsberg, R. et al. (2009) Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14: 70-76.
54. Pisani, P., Bray, F. and Parkin, D.M. ( 2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81.
55. Poon, R.T., Fan, S.T., Tsang, F.H. and Wong, J. ( 2002) Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 235: 466-486.
56. Rizell, M., Andersson, M., Cahlin, C., Hafstrom, L., Olausson, M. and Lindner, P. ( 2008) Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13: 66-70.
57. Rode, A., Bancel, B., Douek, P., Chevallier, M., Vilgrain, V., Picaud, G. et al. (2001) Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25: 327-336.
58. Sala, M., Varela, M. and Bruix, J. ( 2004) Selection of candidates with HCC for transplantation in the meld era. Liver Transpl 10: S4-S9
59. Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois-Mouthon, C., Rey, C. et al. (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41: 307-314.
60. Shetty, K., Timmins, K., Brensinger, C., Furth, E.E., Rattan, S., Sun, W. et al. (2004) Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 10: 911-918.
61. Siegel, A.B., Cohen, E.I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J.J. et al. (2008 a) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998.
62. Siegel, A.B., McBride, R.B., El-Serag, H.B., Hershman, D.L., Brown Jr, R.S., Renz, J.F. et al. (2008 b) Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 103: 120-127.
63. Sotiropoulos, G.C., Kaiser, G.M., Lang, H., Molmenti, E.P., Beckebaum, S., Fouzas, I. et al. (2008 a) Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant Proc 40: 3194-3195.
64. Sotiropoulos, G.C., Lang, H., Saner, F.H., Beckebaum, S., Wandelt, M., Molmenti, E.P. et al. (2008 b) Long-term results after liver transplantation with ‘livers that nobody wants’ within Eurotransplant: a center's experience. Transplant Proc 40: 3196-3197.
65. Thomas, M.B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T. et al. (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059-1067.
66. Thomas, M.B., Morris, J.S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E. et al. (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843-850.
67. Toso, C., Meeberg, G.A., Bigam, D.L., Oberholzer, J., Shapiro, A.M., Gutfreund, K. et al. (2007) de novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83: 1162-1168.
68. Villanueva, A., Chiang, D.Y., Newell, P., Peix, J., Thung, S., Alsinet, C. et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972-1983, 1983 e1971-1911.
69. Vogl, T.J., Naguib, N.N., Nour-Eldin, N.E., Rao, P., Emami, A.H., Zangos, S. et al. (2008) Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol [In press].
70. Woo, H.G., Park, E.S., Cheon, J.H., Kim, J.H., Lee, J.S., Park, B.J. et al. (2008) Gene Expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 14: 2056-2064.
71. Yao, F.Y. ( 2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8: 1982-1989.
72. Yao, F.Y., Ferrell, L., Bass, N.M., Watson, J.J., Bacchetti, P., Venook, A. et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33: 1394-1403.
73. Yao, F.Y., Kerlan Jr, R.K., Hirose, R., Davern 3rd, T.J., Bass, N.M., Feng, S. et al. (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48: 819-827.
74. Yoshiji, H., Kuriyama, S., Yoshii, J., Yamazaki, M., Kikukawa, M., Tsujinoue, H. et al. (1998) Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28: 1489-1496.
75. Zhang, B.H., Yang, B.H. and Tang, Z.Y. ( 2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130: 417-422.
76. Zhou, J., Wang, Z., Wu, Z.Q., Qiu, S.J., Yu, Y., Huang, X.W. et al. (2008) Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 40: 3548-3553.
77. Zhou, L., Huang, Y., Li, J. and Wang, Z. ( 2009a) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol [In press].
78. Zhou, W.P., Lai, E.C., Li, A.J., Fu, S.Y., Zhou, J.P., Pan, Z.Y. et al. (2009 b) A Prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249: 195-202.
79. Zhu, A.X. ( 2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112: 250-259.
80. Zhu, A.X., Blaszkowsky, L.S., Ryan, D.P., Clark, J.W., Muzikansky, A., Horgan, K. et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903.
81. Zhu, A.X., Stuart, K., Blaszkowsky, L.S., Muzikansky, A., Reitberg, D.P., Clark, J.W. et al. (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110: 581-589.
82. Zimmerman, M.A., Trotter, J.F., Wachs, M., Bak, T., Campsen, J., Skibba, A. et al. (2008) Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14: 633-638.